ES2490595T3 - Administración transmucosal de composiciones de fármacos para tratar y prevenir trastornos en animales - Google Patents

Administración transmucosal de composiciones de fármacos para tratar y prevenir trastornos en animales Download PDF

Info

Publication number
ES2490595T3
ES2490595T3 ES06735301.1T ES06735301T ES2490595T3 ES 2490595 T3 ES2490595 T3 ES 2490595T3 ES 06735301 T ES06735301 T ES 06735301T ES 2490595 T3 ES2490595 T3 ES 2490595T3
Authority
ES
Spain
Prior art keywords
administration
composition
oral
meloxicam
transmucosal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES06735301.1T
Other languages
English (en)
Spanish (es)
Inventor
Mark Heit
Antonio Benitz
Dennis Steadman
David Petrick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Application granted granted Critical
Publication of ES2490595T3 publication Critical patent/ES2490595T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61D—VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
    • A61D7/00—Devices or methods for introducing solid, liquid, or gaseous remedies or other materials into or onto the bodies of animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/006—Sprayers or atomisers specially adapted for therapeutic purposes operated by applying mechanical pressure to the liquid to be sprayed or atomised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2250/00—Specially adapted for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Mechanical Engineering (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
ES06735301.1T 2005-02-17 2006-02-17 Administración transmucosal de composiciones de fármacos para tratar y prevenir trastornos en animales Expired - Lifetime ES2490595T3 (es)

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US65396405P 2005-02-17 2005-02-17
US653964P 2005-02-17
US66192005P 2005-03-16 2005-03-16
US661920P 2005-03-16
US66418105P 2005-03-23 2005-03-23
US66418305P 2005-03-23 2005-03-23
US664181P 2005-03-23
US664183P 2005-03-23
US66493805P 2005-03-25 2005-03-25
US66493905P 2005-03-25 2005-03-25
US664939P 2005-03-25
US664938P 2005-03-25
US66552505P 2005-03-28 2005-03-28
US665525P 2005-03-28
US66988805P 2005-04-11 2005-04-11
US669888P 2005-04-11
US67065105P 2005-04-13 2005-04-13
US670651P 2005-04-13
US69394205P 2005-06-27 2005-06-27
US693942P 2005-06-27
PCT/US2006/005575 WO2006089082A2 (en) 2005-02-17 2006-02-17 Transmucosal administration of drug compositions for treating and preventing disorders in animals

Publications (1)

Publication Number Publication Date
ES2490595T3 true ES2490595T3 (es) 2014-09-04

Family

ID=36917071

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06735301.1T Expired - Lifetime ES2490595T3 (es) 2005-02-17 2006-02-17 Administración transmucosal de composiciones de fármacos para tratar y prevenir trastornos en animales

Country Status (7)

Country Link
US (3) US8097614B2 (https=)
EP (2) EP2767163A1 (https=)
JP (2) JP5577021B2 (https=)
AU (1) AU2006214166B2 (https=)
CA (1) CA2597956C (https=)
ES (1) ES2490595T3 (https=)
WO (1) WO2006089082A2 (https=)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7632517B2 (en) 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
US20040136914A1 (en) 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
US20060205681A1 (en) * 2002-06-21 2006-09-14 Maryam Moaddeb Homogenous paste formulations
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
CA2597956C (en) 2005-02-17 2013-07-09 Velcera Pharmaceuticals Transmucosal administration of drug compositions for treating and preventing disorders in animals
EP2015632B1 (en) * 2006-04-19 2015-12-02 Mist Pharmaceuticals, LLC Stable hydroalcoholic oral spray formulations and methods
FR2906140B1 (fr) * 2006-09-22 2008-12-05 Philippe Perovitch Forme galenique pour l'administration par voie trans-muqueuse de principes actifs
US20080118441A1 (en) * 2006-11-19 2008-05-22 Washington Joseph A Compositions and methods for the treatment of gastrointestinal conditions
US20110077200A1 (en) * 2006-12-06 2011-03-31 Somaxon Pharmaceuticals, Inc. Combination therapy using low-dose doxepin for the improvement of sleep
JP2010513525A (ja) * 2006-12-22 2010-04-30 ノヴァデル ファーマ インコーポレイテッド 安定な抗嘔吐経口噴霧製剤および方法
US20090274722A1 (en) * 2007-01-29 2009-11-05 Ligums John E Therapeutic Composition for the Treatment of BPH and ED
WO2008094873A1 (en) * 2007-01-29 2008-08-07 Ligums John E Therapeutic bph composition
MX2009006656A (es) * 2007-03-05 2009-08-07 Merial Ltd Formulaciones homogeneas en pasta y gel.
ES2597104T3 (es) 2007-04-19 2017-01-13 Mary Kay, Inc. Composiciones que contienen extracto de magnolia
CN101801346A (zh) * 2007-05-10 2010-08-11 诺瓦德尔药品公司 抗失眠症组合物及方法
US20100035886A1 (en) 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
US8741918B2 (en) 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
CA2639895C (en) * 2007-10-05 2014-06-10 David Rowland Energizing compositions comprising goji, red clover and polygonum multiflorum, and uses thereof
EP2328585A4 (en) * 2008-09-05 2011-09-21 Troy Lab Pty Ltd TREATMENT OF NEWBORN FOAL WITH MELOXICAM
US20100196286A1 (en) * 2008-12-01 2010-08-05 Armer Thomas A Inhalation delivery methods and devices
FR2940120B1 (fr) * 2008-12-19 2012-07-13 Philippe Perovitch Formulation pour l'administration par voie trans-muqueuse de setrons
WO2010074753A1 (en) 2008-12-23 2010-07-01 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
FR2940911B1 (fr) * 2009-01-13 2012-09-21 Philippe Perovitch Formulation pour l'administration par voie trans-muqueuse buccale de molecules antalgiques et/ou anti-spasmodiques
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
US8663709B1 (en) * 2009-08-31 2014-03-04 Fairhaven Health, Llc Composition and method for fertility therapy using nutritional supplements
CN102781431B (zh) * 2010-02-24 2014-08-27 硕腾有限责任公司 兽医组合物
US20140255453A1 (en) * 2013-03-11 2014-09-11 Jaxsen's Llc Herbal ointment for musculoskeletal and joint-related conditions
CN102933082A (zh) * 2010-04-22 2013-02-13 杰内塞斯实验室股份有限公司 用于防治白蛉和其它吸血昆虫的组合物和方法
US20130190252A1 (en) * 2010-05-18 2013-07-25 Pharmathen S.A. Pharmaceutical formulation containing lipophilic drugs and milk as a solubilizing/dispensing agent and method for the preparation thereof
EP2632553B1 (en) 2010-10-28 2020-01-01 Pacira Pharmaceuticals, Inc. A sustained release formulation of a non-steroidal anti-inflammatory drug
US8840937B2 (en) * 2011-08-02 2014-09-23 Walter Joe FORD, JR. Composition and method for recovery from mild traumatic brain injury
NZ623643A (en) * 2011-10-14 2015-12-24 Troy Lab Pty Ltd Meloxicam based formulations for providing analgesia in sheep
ES2784629T3 (es) 2011-11-29 2020-09-29 Jurox Pty Ltd Composiciones farmacéuticas inyectables estables que comprenden 2-hidroxipropil-beta-ciclodextrina y alfaxalona
JP5828007B2 (ja) 2011-12-21 2015-12-02 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 局所投与型の嚥下障害改善用医薬品
AU2013252491A1 (en) * 2012-04-27 2014-11-06 Troy Laboratories Pty Ltd Combination meloxicam and xylazine therapy in animals
AU2013266141B2 (en) * 2012-05-24 2015-10-01 Innopharma, Inc. Aprepitant injectable formulations
AU2013204134B2 (en) * 2012-06-06 2017-02-02 Elanco New Zealand Ectoparasitic Treatment Method and Composition
FR3000896B1 (fr) 2013-01-14 2016-08-26 Philippe Perovitch Forme galenique pour l'administration de principe(s) actif(s) permettant l'induction acceleree du sommeil et/ou le traitement des troubles du sommeil
US10888707B2 (en) 2013-03-19 2021-01-12 Genovus Biotechnologies Inc. Muscle optimization device and method
US10322063B2 (en) 2013-03-19 2019-06-18 Genovus Biotechnologies Inc. Muscle optimization device and method
US20140288471A1 (en) * 2013-03-19 2014-09-25 Genovus Biotechnologies Inc. Muscle optimization device and method
JPWO2014199486A1 (ja) * 2013-06-13 2017-02-23 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 嚥下障害改善用医薬品
US9974768B2 (en) 2013-06-13 2018-05-22 Meiji Seika Pharma Co., Ltd. Pharmaceutical for improving dysphagia
WO2015093923A1 (es) * 2013-12-19 2015-06-25 Castro Aldrete Jorge Isaac Composiciones veterinarias que comprenden un principio activo y un vehículo farmacéuticamente aceptable para su administración a través de mucosas
US9855227B2 (en) 2015-12-18 2018-01-02 The Procter & Gamble Company Quick dissolving diphenhydramine oral dosage form
US20170232050A1 (en) * 2016-02-16 2017-08-17 David ELLERY Herbal formulation for treating chronic fatigue syndrome
US11331271B2 (en) 2016-05-27 2022-05-17 The Johns Hopkins University Buccal, sublingual and intranasal delivery of fospropofol
EP3541815A4 (en) 2016-11-18 2020-07-15 Pacira Pharmaceuticals, Inc. ZINC MELXICAM COMPLEX MICROPARTICLE MULTIVESICULAR LIPOSOME FORMULATIONS AND METHODS OF MAKING THE SAME
EP4732889A2 (en) 2017-06-07 2026-04-29 Supira Medical, Inc. Intravascular fluid movement devices, systems, and methods of use
KR101816855B1 (ko) 2017-09-29 2018-02-21 서울시립대학교 산학협력단 상황버섯 추출물 또는 베타글루칸을 유효성분으로 함유하는 악취 저감용 조성물
JP7319266B2 (ja) 2017-11-13 2023-08-01 シファメド・ホールディングス・エルエルシー 血管内流体移動デバイス、システム、および使用方法
EP4085965A1 (en) 2018-02-01 2022-11-09 Shifamed Holdings, LLC Intravascular blood pumps and methods of use and manufacture
US12161857B2 (en) 2018-07-31 2024-12-10 Shifamed Holdings, Llc Intravascular blood pumps and methods of use
WO2020073047A1 (en) 2018-10-05 2020-04-09 Shifamed Holdings, Llc Intravascular blood pumps and methods of use
SG11202103255RA (en) * 2018-10-08 2021-04-29 Troikaa Pharmaceuticals Ltd Oromucosal solutions of zolpidem or pharmaceutically acceptable salts thereof
WO2020172714A1 (en) 2019-02-27 2020-09-03 Samson Clinical Pty Ltd Treatment of autoimmune disease
US11478490B1 (en) 2021-03-30 2022-10-25 Epalex Corporation Fospropofol formulations
US11547714B2 (en) 2020-02-05 2023-01-10 Epalex Corporation Fospropofol salts, methods and compositions
US11439653B1 (en) 2021-03-30 2022-09-13 Epalex Corporation Fospropofol formulations
US11628178B2 (en) 2019-03-26 2023-04-18 Epalex Corporation Fospropofol methods and compositions
EP3996797A4 (en) 2019-07-12 2023-08-02 Shifamed Holdings, LLC INTRAVASCULAR BLOOD PUMPS AND METHOD OF USE AND METHOD OF MAKING
US11654275B2 (en) 2019-07-22 2023-05-23 Shifamed Holdings, Llc Intravascular blood pumps with struts and methods of use and manufacture
EP4010046A4 (en) 2019-08-07 2023-08-30 Calomeni, Michael Catheter blood pumps and collapsible pump housings
US12121713B2 (en) 2019-09-25 2024-10-22 Shifamed Holdings, Llc Catheter blood pumps and collapsible blood conduits
EP4034192B1 (en) 2019-09-25 2025-12-24 Supira Medical, Inc. Intravascular blood pump systems and methods of use and control thereof
US12102815B2 (en) 2019-09-25 2024-10-01 Shifamed Holdings, Llc Catheter blood pumps and collapsible pump housings
EP4072650A4 (en) 2019-12-11 2024-01-10 Shifamed Holdings, LLC Descending aorta and vena cava blood pumps
WO2021127503A1 (en) 2019-12-19 2021-06-24 Shifamed Holdings, Llc Intravascular blood pumps, motors, and fluid control
KR20220127849A (ko) 2020-01-10 2022-09-20 트레비 테라퓨틱스, 인코포레이티드 날부핀의 투여 방법
WO2021178579A1 (en) * 2020-03-03 2021-09-10 Alte Verde Llc Cannabis treatment of insomnia, pain, and skin conditions
WO2021247283A1 (en) * 2020-06-04 2021-12-09 Amcyte Pharma, Inc. Delivery of aerosolized micromolar composition concentrations
CN111920805B (zh) * 2020-08-14 2021-11-19 山东省妇幼保健院 富马酸氯马斯汀在抗耐甲氧西林金黄葡萄球菌制剂中的应用
CN116744917A (zh) 2020-09-04 2023-09-12 礼蓝美国公司 适口调配物
US20230390260A1 (en) * 2020-11-25 2023-12-07 Intervet Inc. Method of treatment of pain through buccal administration of flunixin
CA3207194A1 (en) * 2021-02-05 2022-08-11 Epalex Corporation Fospropofol methods and compositions
MX2023014196A (es) * 2021-05-28 2024-07-09 Veterinary Pharmacy Corp Composiciones de complejos solubles en agua y sus métodos.
WO2025179244A1 (en) * 2024-02-23 2025-08-28 Phoenix Biotechnology, Inc. Methods and compositions for improving health

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE632504A (https=) 1962-05-24
US3551554A (en) 1968-08-16 1970-12-29 Crown Zellerbach Corp Enhancing tissue penetration of physiologically active agents with dmso
US3666182A (en) * 1970-04-24 1972-05-30 Chatten Drug & Chem Co Squeeze bottle with means for locating end of delivery tube
US3711606A (en) 1970-09-02 1973-01-16 Crown Zellerbach Corp Enhancing tissue penetration of physiologically active steroidal agents with dmso
US3711602A (en) 1970-10-30 1973-01-16 Crown Zellerbach Corp Compositions for topical application for enhancing tissue penetration of physiologically active agents with dmso
US4122978A (en) * 1975-06-18 1978-10-31 The Gillette Company Pressurized package for dispensing a product in a finely dispersed spray pattern with little dilution by propellant
SE7812207L (sv) 1977-12-01 1979-06-02 Welsh Nat School Med Apparat, forfarande och framstellda produkter for anvendning vid administration av antihistaminer
DE2756113A1 (de) 1977-12-16 1979-06-21 Thomae Gmbh Dr K Neue 4-hydroxy-2h-1,2-benzothiazin- 3-carboxamid-1,1-dioxide, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
US4186855A (en) * 1978-06-19 1980-02-05 Zotos International, Inc. Spray pump actuating and bottle holding device
CA1165240A (en) 1980-07-09 1984-04-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
ZA815698B (en) 1980-08-28 1983-04-27 Lilly Co Eli Intranasal formulation
JPS5758615A (en) 1980-09-26 1982-04-08 Nippon Soda Co Ltd Film agnent and its preparation
CA1208558A (en) 1982-10-07 1986-07-29 Kazuo Kigasawa Soft buccal
DE3338978A1 (de) 1982-10-29 1984-05-03 Basf Ag, 6700 Ludwigshafen Verapamil und gallopamil und ihre physiologisch vertraeglichen salze zur resorptiven anwendung auf den schleimhaeuten des mundes, des nasen-rachen-raums und des rektums
US4557943A (en) 1983-10-31 1985-12-10 Advanced Semiconductor Materials America, Inc. Metal-silicide deposition using plasma-enhanced chemical vapor deposition
GB8522453D0 (en) 1985-09-11 1985-10-16 Lilly Industries Ltd Chewable capsules
DE3544692A1 (de) 1985-12-18 1987-06-19 Bayer Ag Dihydropyridinspray, verfahren zu seiner herstellung und seine pharmazeutische verwendung
US4689233A (en) 1986-01-06 1987-08-25 Siegfried Aktiengesellschaft Coronary therapeutic agent in the form of soft gelatin capsules
US4713243A (en) 1986-06-16 1987-12-15 Johnson & Johnson Products, Inc. Bioadhesive extruded film for intra-oral drug delivery and process
JPH0744940B2 (ja) 1986-12-24 1995-05-17 ライオン株式会社 口腔貼付用基材
JPH0645538B2 (ja) * 1987-09-30 1994-06-15 日本化薬株式会社 ニトログリセリンスプレー剤
HU199678B (en) * 1988-07-08 1990-03-28 Egyt Gyogyszervegyeszeti Gyar Process for producing aerosols containing nitroglicerol
US5128132A (en) 1988-11-22 1992-07-07 Parnell Pharmaceuticals, Inc. Eriodictyon compositions and methods for treating internal mucous membranes
US4935243A (en) 1988-12-19 1990-06-19 Pharmacaps, Inc. Chewable, edible soft gelatin capsule
JP2656338B2 (ja) 1989-01-31 1997-09-24 日東電工株式会社 口腔粘膜貼付製剤
US5011678A (en) 1989-02-01 1991-04-30 California Biotechnology Inc. Composition and method for administration of pharmaceutically active substances
US5158761A (en) 1989-04-05 1992-10-27 Toko Yakuhin Kogyo Kabushiki Kaisha Spray gel base and spray gel preparation using thereof
DE4007705C1 (https=) 1990-03-10 1991-09-26 G. Pohl-Boskamp Gmbh & Co. Chemisch-Pharmazeutische Fabrik, 2214 Hohenlockstedt, De
ES2117642T3 (es) 1990-05-10 1998-08-16 Bechgaard Int Res Preparado farmaceutico que contiene n-glicofuroles y n-etilen glicoles.
US5370862A (en) 1990-06-13 1994-12-06 Schwarz Pharma Ag Pharmaceutical hydrophilic spray containing nitroglycerin for treating angina
US5407663A (en) 1991-04-11 1995-04-18 Eisen; Drore Method of treating inflammatory conditions of the mouth using steroid containing mouthwash which may contain antifungal agents
DE69305759T2 (de) 1992-02-20 1997-06-12 Johannes Louw K Von Wielligh Erzeugnis zur Unterstützung für das Aufgeben des Rauchens
DE69230151T2 (de) 1992-12-04 2000-03-09 Mayor Pharmaceuticals Laboratories, Inc. Sprühfähige analgetische zusammensetzung und verfahren zu irher verwendung
GB2285921A (en) * 1994-01-31 1995-08-02 Leilani Lea Sublingual administration of medicaments
HU214582B (hu) * 1994-07-26 1998-04-28 EGIS Gyógyszergyár Rt. Porlasztható, vérnyomáscsökkentő hatású gyógyszerkészítmény és eljárás előállítására
IL122752A (en) 1995-06-27 2001-07-24 Boehringer Ingelheim Kg Stable preparations for creating propellant-free sprays
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US5869082A (en) 1996-04-12 1999-02-09 Flemington Pharmaceutical Corp. Buccal, non-polar spray for nitroglycerin
US5955098A (en) * 1996-04-12 1999-09-21 Flemington Pharmaceutical Corp. Buccal non polar spray or capsule
EP0910339B1 (en) 1996-04-12 2005-02-02 Novadel Pharma Inc. Buccal polar spray
US20030095926A1 (en) 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US20040136913A1 (en) 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing sumatriptan
US20030077227A1 (en) 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20030077229A1 (en) 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
AU4894697A (en) 1997-10-01 1999-04-23 Flemington Pharmaceutical Corporation Buccal, polar and non-polar spray or capsule
US20040136914A1 (en) 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
US20030095925A1 (en) 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
US20040141923A1 (en) 1997-10-01 2004-07-22 Dugger Harry A. Buccal, polar and non-polar spray containing alprazolam
US20030077228A1 (en) 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating endocrine disorders
US20030082107A1 (en) 1997-10-01 2003-05-01 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
US20050002867A1 (en) 1997-10-01 2005-01-06 Novadel Pharma Inc. Buccal, polar and non-polar sprays containing propofol
US20030185761A1 (en) 1997-10-01 2003-10-02 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US7632517B2 (en) 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
US20050163719A1 (en) 1997-10-01 2005-07-28 Dugger Harry A.Iii Buccal, polar and non-polar spray containing diazepam
US20040136915A1 (en) 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing atropine
US20030190286A1 (en) 1997-10-01 2003-10-09 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma
US20030095927A1 (en) 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
FI974578L (fi) * 1997-12-19 1999-06-20 Orion Yhtymae Oyj Menetelmä levosimendaanin antamiseksi
EP0945134A1 (de) 1998-03-27 1999-09-29 Boehringer Ingelheim Pharma KG Neue galenische Zubereitungsformen von Meloxicam zur oralen Applikation
US6184220B1 (en) 1998-03-27 2001-02-06 Boehringer Ingelheim Pharma Kg Oral suspension of pharmaceutical substance
GB9810671D0 (en) * 1998-05-18 1998-07-15 Pfizer Ltd Anti-pruritic agents
US6428814B1 (en) 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US6849263B2 (en) * 1998-12-21 2005-02-01 Generex Pharmaceutical Incorporated Pharmaceutical compositions for buccal delivery of pain relief medications
US6413965B1 (en) * 1999-06-30 2002-07-02 Pfizer Inc. Compositions and treatment for diabetic complications
US6328035B1 (en) 2000-05-09 2001-12-11 Iep Pharmaceutical Devices Inc. Pneumatic breath actuated inhaler
DE10030345A1 (de) * 2000-06-20 2002-01-10 Boehringer Ingelheim Vetmed Hochkonzentrierte stabile Meloxicamlösungen
US20020035107A1 (en) 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
KR100514337B1 (ko) * 2000-06-27 2005-09-13 메이지 세이카 가부시키가이샤 팽화 초콜릿 함유 중공 과자 및 그 제조 방법
US20040204413A1 (en) * 2001-01-26 2004-10-14 Joaquina Faour Pharmaceutical compositions containing a COX-II inhibitor and a muscle relaxant
DE10161077A1 (de) * 2001-12-12 2003-06-18 Boehringer Ingelheim Vetmed Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion
TW200403072A (en) 2002-01-23 2004-03-01 Upjohn Co Combination therapy for the treatment of bacterial infections
FI20022007A0 (fi) * 2002-11-08 2002-11-08 Juvantia Pharma Ltd Oy Oromukosaalinen valmiste ja menetelmä sen valmistamiseksi
GB0229808D0 (en) 2002-12-20 2003-01-29 Glaxo Group Ltd Novel compositions
US8512727B2 (en) 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
KR20050115276A (ko) * 2003-03-11 2005-12-07 아라키스 리미티드 신규한 조성물
CA2597956C (en) 2005-02-17 2013-07-09 Velcera Pharmaceuticals Transmucosal administration of drug compositions for treating and preventing disorders in animals

Also Published As

Publication number Publication date
EP2767163A1 (en) 2014-08-20
JP5577021B2 (ja) 2014-08-20
EP1848270B1 (en) 2014-05-21
EP1848270A4 (en) 2012-07-25
JP2008530233A (ja) 2008-08-07
US8097614B2 (en) 2012-01-17
US20150174060A1 (en) 2015-06-25
US20120289470A1 (en) 2012-11-15
AU2006214166A1 (en) 2006-08-24
US8940271B2 (en) 2015-01-27
CA2597956A1 (en) 2006-08-24
WO2006089082A2 (en) 2006-08-24
JP2013067643A (ja) 2013-04-18
WO2006089082A3 (en) 2007-07-12
AU2006214166B2 (en) 2011-09-29
US20060239928A1 (en) 2006-10-26
JP5681693B2 (ja) 2015-03-11
CA2597956C (en) 2013-07-09
EP1848270A2 (en) 2007-10-31

Similar Documents

Publication Publication Date Title
ES2490595T3 (es) Administración transmucosal de composiciones de fármacos para tratar y prevenir trastornos en animales
AU2010248776B2 (en) Sublingual dexmedetomidine compositions and methods of use thereof
ES2684491T3 (es) Tecnología para la administración de fármacos
CA2673049C (en) Stable anti-nausea oral spray formulations and methods
US11213484B2 (en) Dipivefrin orally disintegrating tablet formulations
AU2012200031B9 (en) Transmucosal administration of drug compositions for treating and preventing disorders in animals
CA2819963A1 (en) Transmucosal administration of drug compositions for treating and preventing disorders in animals
AU2013263787B2 (en) Transmucosal administration of drug compositions for treating and preventing disorders in animals
US9987267B2 (en) Transdermal formulations of pergolide and uses thereof
US12109303B2 (en) Orally dissolving antimicrobial film compositions and methods of their use
HK1168302B (en) Sublingual dexmedetomidine compositions and methods of use thereof